Mycro3
- CAS No.
- 944547-46-0
- Chemical Name:
- Mycro3
- Synonyms
- Mycro3;Mycro-3, >98%;Mycro 3 ，S0249;Mycro 3, 10 mM in DMSO;dimerization,Mycro 3,pancreatic,inhibit,adenocarcinoma,ductal,c-Myc,Inhibitor,PDA,Autophagy,Mycro3,MAX,Myc;ethyl 5-[7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-amido]-1-phenyl-1H-pyrazole-4-carboxylate;Ethyl 5-(7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamido)-1-phenyl-1H-pyrazole-4-carboxylate;Ethyl 5-[[7-(chlorodifluoromethyl)-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidin-2-yl]formamido]-1-phenyl-1H-pyrazole-4-carboxylate;ethyl 5-[[7-[chloro(difluoro)methyl]-5-(furan-2-yl)pyrazolo[1,5-a]pyrimidine-2-carbonyl]amino]-1-phenylpyrazole-4-carboxylate;1H-Pyrazole-4-carboxylic acid, 5-[[[7-(chlorodifluoromethyl)-5-(2-furanyl)pyrazolo[1,5-a]pyrimidin-2-yl]carbonyl]amino]-1-phenyl-, ethyl ester
- CBNumber:
- CB13067564
- Molecular Formula:
- C24H17ClF2N6O4
- Molecular Weight:
- 526.88
- MDL Number:
- MFCD03409284
- MOL File:
- 944547-46-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Mycro 3 ≥95% | 37767 | 500μg | $90 |
| Mycro 3 ≥95% | 37767 | 1mg | $160 |
| Mycro 3 ≥95% | 37767 | 5mg | $710 |
| Mycro 3 ≥95% | 37767 | 10mg | $1064 |
| Mycro 3 98.11% | CS-7586 | 2mg | $157 |
| More product size | |||
| Density | 1.53±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO : ≥ 100 mg/mL (189.80 mM) |
| pka | 6.95±0.46(Predicted) |
| form | Solid |
| color | Light yellow to yellow |
| InChIKey | YPPNLSKYXDXQGD-UHFFFAOYSA-N |
| SMILES | N1(C2=CC=CC=C2)C(NC(C2C=C3N(N=2)C(C(Cl)(F)F)=CC(C2=CC=CO2)=N3)=O)=C(C(OCC)=O)C=N1 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P264-P280-P302+P352-P321-P332+P313-P362-P305+P351+P338-P337+P313-P261-P271-P304+P340-P312-P403+P233-P405-P501 |
Mycro3 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 37767 | Mycro 3 ≥95% | 944547-46-0 | 500μg | $90 | 2026-04-30 | Buy |
| Cayman Chemical | 37767 | Mycro 3 ≥95% | 944547-46-0 | 1mg | $160 | 2026-04-30 | Buy |
| Cayman Chemical | 37767 | Mycro 3 ≥95% | 944547-46-0 | 5mg | $710 | 2026-04-30 | Buy |
| Cayman Chemical | 37767 | Mycro 3 ≥95% | 944547-46-0 | 10mg | $1064 | 2026-04-30 | Buy |
| ChemScene | CS-7586 | Mycro 3 98.11% | 944547-46-0 | 2mg | $157 | 2026-06-04 | Buy |
Mycro3 Chemical Properties,Uses,Production
Uses
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc[1]. Mycro 3 could be used for the research of pancreatic cancer[2].
Biological Activity
Mycro 3 is a potent selective Myc-Max dimerization inhibitor. It can be used in pancreatic cancer research.
in vitro
Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). It has a superior specificity profile to its predecessors. It inhibits the interaction between c-Myc and Max. It has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA.
in vivo
Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells[2].
| Animal Model: | Moribund Pdx1-cre/KRAS* mice bearing pancreatic ductal adenocarcinoma (PDA)[2] |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; daily for two months |
| Result: | Increased survival time. Mycro 3 administration was discontinued after two months, the mouse survived for an additional month. |
target
Myc-MAX dimerization
References
[1] Chen BJ, et al. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014 Sep 13;10(10):1084-96. DOI:10.7150/ijbs.10190
[2] Dimitris Stellas, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014 Oct 11;106(12):dju320. DOI:10.1093/jnci/dju320
Mycro3 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30224 | 58 |
| BOC Sciences | 16314854226; +16314854226 | inquiry@bocsci.com | United States | 19853 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 | sales@molcore.com | China | 49734 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39037 | 58 |
| ShenZhen Trendseen Biological Technology Co.,Ltd. | 13417589054 | trendseenbio@gmail.com | China | 11680 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8615965530500 | nickzhang@hangyubiotech.com | China | 9945 | 58 |
